Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype

Multiple myeloma (MM) cells specifically attract peripheral-blood monocytes, while interaction of MM with bone marrow stromal cells (BMSCs) significantly increased monocyte recruitment (p<0.01). The CXCL12 chemokine, produced by both the MM and BMSCs, was found to be a critical regulator of monocyte migration. CXCL12 production was up-regulated under MM-BMSCs co-culture conditions, whereas blockage with anti-CXCR4 antibodies significantly abrogated monocyte recruitment toward a MM-derived conditioned medium (p<0.01). Furthermore, elevated levels of CXCL12 were detected in MM, but not in normal BM samples, whereas malignant MM cells often represented the source of increased CXCL12 in the BM. Blood-derived macrophages effectively supported MM cells proliferation and protected them from chemotherapy-induced apoptosis. Importantly, MM cells affected macrophage polarization, elevating the expression of M2-related scavenger receptor CD206 in macrophages and blocking LPS-induced TNFα secretion (a hallmark of M1 response). Of note, MM-educated macrophages suppressed T-cell proliferation and IFNγ production in response to activation. Finally, increased numbers of CXCR4-expressing CD163+CD206+ macrophages were detected in the BM of MM patients (n=25) in comparison to MGUS (n=11) and normal specimens (n=8). Taken together, these results identify macrophages as important players in MM tumorogenicity, and recognize the CXCR4/CXCL12 axis as a critical regulator of MM-stroma interactions and microenvironment formation.

[1]  Arnon Nagler,et al.  Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140 , 2013, Clinical Cancer Research.

[2]  Sevinç Şahin,et al.  Tumor-associated macrophages as a prognostic parameter in multiple myeloma , 2013, Annals of Hematology.

[3]  A. Trumpp,et al.  Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells. , 2012, Blood.

[4]  S. Rankin Chemokines and adult bone marrow stem cells. , 2012, Immunology letters.

[5]  H. Dolstra,et al.  Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention. , 2012, Blood.

[6]  A. Nagler,et al.  Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions , 2012, Clinical & developmental immunology.

[7]  R. Kerbel,et al.  Combined blockade of integrin-α4β1 plus cytokines SDF-1α or IL-1β potently inhibits tumor inflammation and growth. , 2011, Cancer research.

[8]  M. Merad,et al.  Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche , 2011, The Journal of experimental medicine.

[9]  S. Sánchez-Ramón,et al.  The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. , 2011, Blood.

[10]  G. Pizzolo,et al.  Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12 , 2010, Molecular Cancer.

[11]  A. Mantovani,et al.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm , 2010, Nature Immunology.

[12]  C. Bokemeyer,et al.  The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients. , 2010, Experimental hematology.

[13]  S. Gordon,et al.  Alternative activation of macrophages: mechanism and functions. , 2010, Immunity.

[14]  S. Yaccoby Advances in the understanding of myeloma bone disease and tumour growth , 2010, British journal of haematology.

[15]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[16]  H. Vogel,et al.  Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. , 2010, The Journal of clinical investigation.

[17]  Charles P. Lin,et al.  RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. , 2009, Blood.

[18]  M. Dimopoulos,et al.  Increased expression of macrophage inflammatory protein-1α on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma , 2009, Leukemia.

[19]  A. Dietz,et al.  Tumor‐associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma , 2009, American journal of hematology.

[20]  G. Basak,et al.  Multiple myeloma bone marrow niche. , 2009, Current pharmaceutical biotechnology.

[21]  P. Allavena,et al.  Macrophage polarization in tumour progression. , 2008, Seminars in cancer biology.

[22]  S. Vandenberg,et al.  HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. , 2008, Cancer cell.

[23]  C. Bokemeyer,et al.  CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation , 2008, Haematologica.

[24]  D. Ribatti,et al.  Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma , 2008, Oncogene.

[25]  Kenneth C. Anderson,et al.  Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets , 2007, Nature Reviews Cancer.

[26]  Jiasen Cheng,et al.  Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. , 2007, Blood.

[27]  L. Ivashkiv,et al.  Apoptotic cells inhibit LPS-induced cytokine and chemokine production and IFN responses in macrophages. , 2007, Human immunology.

[28]  W. Dalton,et al.  Synopsis of a Roundtable on Validating Novel Therapeutics for Multiple Myeloma , 2006, Clinical Cancer Research.

[29]  G. Roodman,et al.  Chemokines in multiple myeloma. , 2006, Experimental hematology.

[30]  P. Allavena,et al.  Role of tumor-associated macrophages in tumor progression and invasion , 2006, Cancer and Metastasis Reviews.

[31]  D. Ribatti,et al.  Bone marrow angiogenesis in multiple myeloma , 2006, Leukemia.

[32]  J. Pollard,et al.  Distinct role of macrophages in different tumor microenvironments. , 2006, Cancer research.

[33]  Weiping Zou,et al.  Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.

[34]  A. Zannettino,et al.  Elevated Serum Levels of Stromal-Derived Factor-1α Are Associated with Increased Osteoclast Activity and Osteolytic Bone Disease in Multiple Myeloma Patients , 2005 .

[35]  M. Tsan,et al.  Heat shock protein and innate immunity. , 2004, Cellular & molecular immunology.

[36]  P. Allavena,et al.  Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. , 2004, Seminars in cancer biology.

[37]  P. Allavena,et al.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.

[38]  A. Hidalgo,et al.  Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. , 2001, Blood.

[39]  M. Schmid Combined blockade of integrin-alpha4beta1 plus cytokines SDF-1alpha or IL-1beta potently inhibits tumor inflammation and growth , 2011 .

[40]  D. Chauhan,et al.  Bone marrow microenvironment and the identification of new targets for myeloma therapy , 2009, Leukemia.

[41]  G. Roodman Novel targets for myeloma bone disease. , 2008, Expert opinion on therapeutic targets.

[42]  A. Zannettino,et al.  Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. , 2005, Cancer research.

[43]  J. Pollard Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.

[44]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.